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Abstract: Background: To avoid morbidity and limited availability associated with autografts,
synthetic calcium phosphate (CaP) ceramics were extensively developed and used as bone filling
materials. Controlling their induced-inflammatory response nevertheless remained a major
concern. Strontium-containing CaP ceramics were recently demonstrated for impacting cytokines’
secretion pattern of human primary monocytes. The present study focuses on the ability of
strontium-containing CaP to control the human primary bone cell production of two major
inflammatory and pro-osteoclastogenic mediators, namely MCP-1 and Gro-α, in response to ceramics
particles. Methods: This in vitro study was performed using human primary osteoblasts in which
their response to ceramics was evaluated by PCR arrays, antibody arrays were used for screening and
real-time PCR and ELISA for more focused analyses. Results: Study of mRNA and protein expression
highlights that human primary bone cells are able to produce these inflammatory mediators and reveal
that the adjunction of CaP in the culture medium leads to their enhanced production. Importantly,
the current work determines the down-regulating effect of strontium-substituted CaP on MCP-1 and
Gro-α production. Conclusion: Our findings point out a new capability of strontium to modulate
human primary bone cells’ communication with the immune system.
Keywords: human primary bone cells; cytokines; strontium; calcium-phosphate
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1. Introduction
Despite much research in the biomaterial field, the gold standard technique to treat large bone
defects still consists of autologous bone grafts. Due to the aging of the population, the morbidity,
and the limited amount of harvestable autografts, as well as the risks of disease transmission or
immunogenic responses associated with allografts, the development of synthetic bioactive materials
containing active molecules or ions continues to spread [1]. The development of innovative
biomaterials tends to increase the efficiency and the capability of practitioners to treat aged or
diseased patients. New strategies have emerged to develop biomaterials leading to faster and better
osseointegration. Synthetic calcium phosphate (CaP) ceramics are widely used as bone filling materials
as a substitute to auto/allograft thanks to their similarity with the inorganic phase of bone and their
osteoconductive properties. Despite their good biocompatibility and their ability to increase the
integration of coated implants [2–4], CaP materials demonstrate feeble bone cell stimulation and
have a tendency to fragment and generate particles which are known to provoke a pro-inflammatory
response, which could be harmful and affect long term implant survival [5–8]. Alternative ceramics
have been developed in order to upgrade their bioactive properties [9], to control the inflammatory
process, and to enhance their survival time [10–12].
So far, researchers have studied the communication between bone forming cells (osteoblasts) and
bone resorbing cells (osteoclasts, giant multinucleated cells formed by the merging of precursors
deriving from the monocyte lineage) to better understand diseases due to the dysregulation of
osteoformation/osteolysis balance [13–16]. Such diseases could be local (i.e., periodontitis, aseptic
loosening . . . ) [16] or systemic (i.e., osteoporosis . . . ) [13] but always involve inflammatory processes.
Research work has been mainly focused on osteoclast precursors’ recruitment, activation, and fusion.
Nevertheless, the role of osteoblasts was downplayed though it has to be considered. Osteoblasts
are actually described as producers of cytokines and chemokines such as IL-6, IL-8, and CCL2
(MCP-1) [17–21] in response to pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α)
and IL-1β [21–23]. As such, considering osteoblasts as key cells in the control of bone balance seems
tempting. This hypothesis is sustained by recent studies that have highlighted the role of MCP-1 in
the formation of osteoclasts and Foreign Body Giant Cells [24] and in the recruitment of osteoclast
precursors and stimulation of osteoclastogenesis [25,26]. Recent studies have also implicated members
of the CXCL family in osteoclast formation [27,28].
In light of these findings, it seems necessary to take cytokine production by bone forming
cells into account when developing new biomaterials. Strontium (Sr) is well-known to modify
bone balance towards the osteogenic pathway and it has been widely used in treatments for
osteoporosis [29]. Strontium has also been demonstrated to be able to enhance pre-osteoblastic
cell replication, to stimulate bone formation [30] and to decrease cytokine production [31] and bone
resorption [32,33]. Moreover, recent data demonstrated that Sr-substituted CaP particles were able
to modulate cytokine production by human monocytes [34]. Strontium ranelate was furthermore
shown to inhibit titanium-induced osteolysis by restraining inflammatory osteoclastogenesis due
to wear particles in a mice model. This study revealed that strontium ranelate obviously reduced
the secretion of tumor necrosis factor-α and interleukin-1β locally synthesized in animals which
received titanium particles [31]. Of interest, to our knowledge, no studies focused on the effect of
strontium on the expression or synthesis of CCL2 and CXCL1 (Gro-α) chemokines. In the present work,
CaP ceramics and CaP biphasic material substituted with five percent of strontium [11] were used to
challenge human primary bone cell responses to Ca-P biomaterials. MCP-1 and Gro-α production
were specifically assessed and the inflammatory cytokine secretion profile of primary bone cells in
response to biomaterial particles was investigated to shed light on putative key pro-inflammatory
mediators that could be down-regulated by strontium substitution.
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2. Results
2.1. CCL2 (MCP-1) and CXCL1 (Gro-α) Expression and Synthesis in Basal Conditions
First, CCL2 (MCP-1) and CXCL1 (Gro-α) expression and synthesis were measured in basal
conditions to assess the capability of human primary bone cells to produce both the latter cytokines.
The results highlight an important expression (Figure 1A) and production (Figure 1B) of CCL2 (MCP-1)
and lower expression and production of CXCL-1 (Gro-α). No differences could be observed between
the three culture times (7, 14, and 21 days).
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Figure 1. Gro-α and MCP-1 are produced by human primary bone cells in basal culture conditions.
(A) Human primary bone cells’ cytokine expressions were measured using Real-Time Polymerase
Chain Reaction (RT-PCR) after 7, 14, and 21 days of culture. The HPRT1 gene was used as the
housekeeping g e (HKG); (B) Cytokine concentrations were measured in huma primary bo e cell
culture super atants after 7, 14, and 21 days. Both experiments were performed on 8 independent
donors i d plic te. Red bars represent median values. Bla k poi ts r present maximum and minimum
values. Black bars represent first and ninth deciles and the limits of rectangles represent first and
third quartiles.
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2.2. Modulation of CCL2 (MCP-1) and CXCL1 (Gro-α) Expression and Synthesis by Human Primary Bone
Cells after CaP Particles Contact
To highlight the effect of strontium substitution in CaP particles on the expression and synthesis
of CCL2 (MCP-1) and CXCL1 (Gro-α), strontium-substituted particles were assessed comparatively
with non-substituted ones. Strontium chloride was used as a control. Both studied cytokines revealed
a transient increase of expression and synthesis in contact with Biphasic Calcium Phosphate (BCP)
during the study (Figures 2 and 3). After 7 days and 14 days of culture with BCP particles, an increase
of CCL2 transcription could be observed as well as an increase of MCP-1 secretion, whereas after
21 days both signals decreased. After 7 and 14 days, human primary bone cell exposition to BCP5% did
not induce any variation in MCP-1 production (nor at the transcriptional or the translational levels),
whereas after 21 days the MCP-1 concentration was decreased in cell culture supernatant without
any mRNA variation. Over the same period, SrCl2 induced a cellular response similar to BCP5% with
a unique difference; a slight increase at the mRNA level after 7 days. Of note, after 7 and 14 days,
MCP-1 concentration was significantly lower in BCP5%-stimulated cell supernatants in comparison
with the BCP condition (Figure 2A,B). After 14 days, BCP particles also induced an increase in CCL2
expression compared to BCP5% conditions.
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Figure 2. Strontium effect on MCP-1 production by human primary bone cells. (A) CCL2 and mRNA
expression was evaluated by RT-PCR analysis performed (as described in the Materials and Methods
section) after 7, 14 and 21 days of stimulation by BCP, BCP5%, and SrCl2. Experiments were performed
on 5 independent donors in duplicate. Data are shown as specific variation of target genes mRNA using
the 2−∆∆Ct method (HPRT1 was used as internal control); (B) MCP-1 concentration was measured in
cell supernatants after 7, 14, and 21 days of stimulation by BCP, BCP5%, and SrCl2. * means p < 0.05
when compared with cont ol and # p < 0.05 whe co pared with BCP. R d bars represent median
values. Black points represent maximum and mi imum values. Black bars represent first and ninth
deciles and the limits of white rectangles represents first and third quartiles.
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Regarding Gro-α (Figure 3) after 7 days, BCP particles induced an increased CXCL1 mRNA
expression but failed to induce any variations compared to the control condition at the protein level.
After 14 days, increased CXCL1 mRNA production and Gro-α concentration were measured when
cells were placed with BCP particles, whereas after 21 days only an increase in Gro-α concentration was
induced. Under BCP5% stimulation, mRNA stayed at the basal level after 7 days and was increased after
14 days, and BCP5% elicited a decrease in Gro-α concentration after both 7 and 14 days. After 21 days,
neither CXCL1 mRNA production nor Gro-α concentration were affected by contact with BCP5%
particles. Human primary bone cell treatment with SrCl2 did not induce any variations in CXCL1
mRNA expression but elicited a decrease in Gro-α concentration after 7 days. After 14 and 21 days,
SrCl2 failed to induce any variations both at the mRNA and protein levels. Of importance, CXCL1
mRNA was significantly reduced compared to the BCP condition after 7 and 14 days and the protein
level was also decreased by BCP5% condition at all times.
Materials 2016, 9, 985  5 of 14 
 
Regarding Gro-α (Figure 3) after 7 days, BCP particles induced an increased CXCL1 mRNA 
expression but failed to induce any variations compared to the control condition at the protein level. 
After 14 days, increased CXCL1 mRNA production and Gro-α concentration were measured when 
lls were placed with BCP particles, where s after 21 day  only an increase in Gro-α concentration 
was i uced. Under BCP5% stimulation, mRNA stayed at the basal level after 7 days and was 
increased after 14 days, and BCP5% elicited a decrease in Gro-α concentration after both 7 and 14 days. 
After 21 days, neither CXCL1 mRNA production nor Gro-α concentration were affected by contact 
with BCP5% particles. Human primary bone cell treatment with SrCl2 did not induce any variations 
in CXCL1 mRNA expression but elicited a decrease in Gro-α concentration after 7 days. After 14 and 
21 days, SrCl2 failed to induce any variations both at the mRNA and protein levels. Of importance, 
CXCL1 mRNA was significantly reduced compared to the BCP condition after 7 and 14 days and the 
protein level was also decreased by BCP5% condition at all times. 
 
Figure 3. Strontium effect on Gro-α production by human primary bone cells. (A) CXCL1 and mRNA 
production were evaluated by RT-PCR analysis performed (as described in the Materials and 
Methods section) after 7, 14, and 21 days of stimulation by BCP, BCP5%, and SrCl2. Experiments were 
performed on 5 independent donors in duplicate. Data are shown as specific variation of target genes 
mRNA using the 2−ΔΔCt method (HPRT1 was used as internal control); (B) Gro-α concentration was 
measured in cell supernatants after 7, 14, and 21 days of stimulation by BCP, BCP5%, and SrCl2. * means 
p < 0.05 when compared with control and # p < 0.05 when compared with BCP. Red bars represent 
median values. Black points represent maximum and minimum values. Black bars represent first and 
ninth deciles and the limits of white rectangle represents first and third quartiles. 
0
1
10
[G
ro
-α]
 v
ar
ia
tio
n 
ve
rs
us
 c
on
tro
l
BCP  BCP5% SrCl2 BCP  BCP5% SrCl2 BCP  BCP5% SrCl2
Day 7 Day 14 Day 21
B
*
#
*
*
*
*
#
#
0
1
10
C
X
C
L1
m
R
N
A
va
ria
tio
n 
ve
rs
us
 
co
nt
ro
l
BCP  BCP5% SrCl2 BCP  BCP5% SrCl2 BCP  BCP5% SrCl2
A
Day 7 Day 14 Day 21
*
*
*
#
#
Figure 3. Strontium effect on Gro-α production by human primary bone cells. (A) CXCL1 and mRNA
production were evaluated by RT-PCR analysis performed (as described in the Materials and Methods
section) after 7, 14, and 21 days of stimulation by BCP, BCP5%, and SrCl2. Experiments were performed
on 5 independent donors in duplicate. Data are shown as specific variation of target genes mRNA
using the 2−∆∆Ct method (HPRT1 was used as internal control); (B) Gro-α concentration was measured
in cell supernata ts after 7, 14, and 21 days of stimulation by BCP, BCP5%, and SrCl2. * means p < 0.05
when compared with control and # p < 0.05 when compared with BCP. Red bars represent median
values. Black points represent maximum and minimum values. Black bars represent first and ninth
deciles and the limits of white rectangle represents first and third quartiles.
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To summarize, we have demonstrated that cells in contact with BCP5% exhibited a lower
production of CCL2 and CXCL1 than those exposed to BCP at 7 and 14 days of culture, and SrCl2
induced quite the same response pattern as BCP5%.
2.3. Cytokine Production and the Effect of Biphasic Calcium-Phosphate Particles
Since interesting results were obtained while studying only two cytokines, we decided to
investigate the ability of human primary bone cells to produce a wider range of pro-inflammatory
mediators at the protein level in basal conditions (Figure 4), but also in the presence of the BCP
particles (Tables 1 and 2), using antibody array techniques. IL-6, MCP-1, IL-8, Gros, EGF, and
RANTES represent the main produced cytokines, and among them three showed high production
levels (IL-6, MCP-1, and IL-8) (Table 1). Only IL-6 and MCP-1 were notably detected in all conditions.
Others were synthesized by human primary bone cells of one or two of the three initial donors,
independently of the studied condition. Finally, GCSF, Gro-α, IL-5, IL-12, IL-13, IFN-γ, MIG, MIP-1δ,
TNF-α, and Thrombopoietin were not detected using this technique. We then focused on the six most
produced cytokines.
Table 1. Cytokine array inflammatory mediator screening. Values express the average (n = 3) level of
secretion (arbitrary units) for each mediator normalized with internal positive controls and an internal
negative control. Frequency represents the number of conditions where cytokines could be detected.
Level of Production Cytokines Frequency of Detection Relative Mean Level Detected
Produced by all donors
in all conditions
IL-6 36 66
MCP-1 36 47
Produced by a majority
of donors in a majority
of conditions
IL-8 26 40
GRO 19 12
EGF 19 9
RANTES 18 8
Produced by a minority
of donors in a minority
of conditions
IL-7 15 9
ENA-78 11 6
TARC 10 6
IL-3 9 6
Leptin 9 5
IGF-1 8 5
GM-CSF 7 5
I-309 7 5
IL-1α 7 4
MCSF 6 4
SCF 6 5
TGF-β1 6 4
TNF-α 6 5
Oncostatin M 6 4
SDF-1 5 5
Angiogenin 5 7
PDGF BB 5 4
IL-10 2 4
MCP-2 2 5
MCP-3 2 4
VEGF 2 4
IL-1β 1 4
IL-2 1 5
IL-4 1 4
IL-15 1 4
MDC 1 4
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In basal conditions, time dependency could be hypothesized for IL-6, MCP-1, IL-8, and Gros,
whereas EGF level remained close to the detection threshold and tends to decrease over time,
as observed for RANTES (Figure 4).Materials 2016, 9, 985  7 of 14 
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Figure 4. Relative cytokine production in human primary bone cell supernatants in basal culture
conditions, measured by antibody arrays. The minimal (bottom box), median (inside box line), and
maximal (top box) production are shown from 3 independent donors.
In the presence of BCP, a transient increase of cyt kine production could be observed for all of the
six most pr duced cytokines after 7 days of interactio s (Table 2). Apart from MCP-1, a decrease could
be observe on day 14. After 21 days of culture in the presence of BCP, IL-6, MCP-1, IL-8 and Gros
productions were minor compared to the control. Conversely, for EGF and RANTES, BCP induced
an increased production at day 21.
The adjunction of strontium tended to reduce IL-6 production as revealed by the level of
production seen in BCP5% and SrCl2 conditions compared to basal and BCP conditions after 7 and
14 days of contact, where strontium was allowed to cut the IL-6 production versus the control only.
This ifference was also observed in MCP-1 production on day 7 and 14. After an initial increase
of IL-8 pr duction on day 7, due to the incorp ration of both particles, B tended t reduce the
production on day 14 and 21. BCP5% tends to restor the IL-8 production to the basal st t on day
14 and 21. Production of ros presented a transient increase of production on day 7 when BCP was
employed. This tended to be regulated on days 14 and 21 and soluble or particulate strontium led
to an increase of the production of total Gros for all times studied. No clear variation patterns were
observed in the presence of strontium for EGF and RANTES.
Our results demonstrated that human primary bone cells are able to secrete some inflammatory
mediators at the basal level, and that they are able to modulate this production in response to BCP
particles and BCP5% particles.
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Table 2. Average values of cytokine production in human primary bone cell culture supernatants in
BCP, BCP5%, and SrCl2-stimulated conditions measured by antibody arrays. NA means not achievable.
Cytokines
Day 7 Day 14 Day 21
Basal BCP BCP5% SrCl2 Basal BCP BCP5% SrCl2 Basal BCP BCP5% SrCl2
IL-6 63.46 68.80 57.50 43.65 63.63 61.75 52.24 59.61 91.41 69.82 78.74 85.96
MCP-1 29.31 53.58 42.87 30.02 35.85 50.81 47.32 37.59 63.52 55.65 62.41 69.94
IL-8 20.94 28.16 37.63 29.02 9.32 6.42 9.97 8.73 57.01 41.55 43.17 56.64
GROs 2.10 4.03 6.68 3.47 5.02 1.62 6.16 7.16 10.17 9.79 12.20 10.26
EGF 4.87 9.35 10.93 8.27 5.57 1.83 7.19 2.46 NA 8.00 7.19 2.46
RANTES 5.75 7.03 7.72 7.72 3.12 1.92 2.01 2.16 NA 5.15 4.79 6.52
3. Discussion
To our knowledge, this study is the first to evaluate the effect of strontium—especially of BCP
containing strontium—on CCL2/MCP-1 and CXCL1/Gro-α expression and production by human
primary bone cells. Similar results were obtained when the MCP-1 production was assessed by
ELISA or cytokine arrays. Interestingly, Gro-α could not be detected when using cytokine arrays
even if total Gros was detected. The detection threshold chosen by the manufacturer could explain
this result since those arrays are mainly destined to measure the production of high producing
cells from the inflammatory system and since Gro-α is produced in a lower amount than MCP-1.
The two most expressed cytokines detected in the present study are IL-6 and MCP-1. In many
bone diseases, inflammation is recognized as a key factor which is able to promote and enhance
bone destruction [17,35]. Among pro-inflammatory factors acting on bones, TNF-α, IL-6, IL-1β, and
the receptor activator of nuclear factor (NF)-κB (RANK)/RANK ligand (RANKL)/osteoprotegrin
(OPG) triad [22,35] have been largely described for their tight regulation of mechanisms that govern
osteoclast development and activity. Nevertheless, if it is also found that osteoblasts are highly
responsive to such immune-derived cytokines, to date, very few studies have tried to assess the ability
of primary osteoblasts to express and synthesize cytokines and chemokines despite their central role
in communication with the immune system. The present study revealed that human primary bone
cells have the capacity to express a wide range of chemokines dedicated to the recruitment and the
activation of the monocytes/macrophages (MCPs) and the neutrophils (Gros, IL-8). In the presence of
BCP particles, human primary bone cells increased the expression and synthesis of pro-osteoclastic
cytokines (Gros, IL-6, IL-8, MCP-1), and some factors which are able to enhance angiogenesis (EGF).
They have all been identified to impact the bone balance [36–40]. In addition to the demonstration
that the adjunction of BCP in the cell medium tended to increase CXCL1 expression and secretion by
human primary bone cells, this work also highlighted that the use of strontium containing BCP allows
the reduction of the production of Gro-α and MCP-1. Of importance, MCP-1 is known to be involved
in osteoclast differentiation, especially in the cell–cell fusion of monocytic precursors leading to the
production of active osteoclasts [25,39,41,42]. It has also been proven that exogenous MCP-1 applied
to inflamed bone enhances the recruitment of monocytes which produce factors including (but not
limited to) prostaglandins, platelet-derived growth factor, IL-1, and TNF-α, which influence bone
metabolism in an osteoclastic way [39,41]. Moreover, works using murine macrophages cultured on
Biocoat™ osteologic disks have allowed the identification of a correlation between mineral dissolution
activity (due to osteoclastic commitment) and MCP-1 concentration added in the culture medium.
Of importance, other researchers have demonstrated such an effect with the same range of cytokine
concentrations that were measured in our present study [25,43,44]. In addition, in vivo injection
of comparable MCP-1 concentrations into the mice distal femoral canal has induced a systemic
recruitment of macrophages [45,46]. Therefore, it can be hypothesized that implantation of BCP
may induce an increase of the osteoclast recruitment and differentiation through the modification of
the cytokines in the bone micro-environment. The strontium substitution may lead, as previously
demonstrated in monocytes [31], to a lower amount of osteoclastogenic cytokine secretion by human
primary bone cells in their micro-environment.
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Of interest, Gro-α is known to be a potent neutrophil chemoattractant with recognized roles in
angiogenesis and inflammation, but it is also considered now as having a local action through the
PTHR1, itself being able to stimulate cells of the osteoblastic lineage to release chemokines capable of
attracting osteoclast precursors to the bone environment [36]. More recent studies have highlighted
that Gro-α and Gro-β are necessary for LPS-induced osteoclast formation [27] and are able to efficiently
accelerate osteoclast maturation leading us to consider Gro-α and Gro-β as key cytokines in the
bone physiology [28]. In that way, IL-6 tends to present similar modifications of production similar
to MCP-1. Strontium tends to reduce the production of IL-6 which is known to be preferentially
produced in response to local bone-resorbing agents, and to induce bone resorption both alone
and in accordance with other bone-resorbing agents [47]. In addition, IL-6 exhibits a dual role in
osteoclastogenesis. On the one hand, IL-6 may directly act on osteoclast progenitors and suppress their
differentiation [48,49]; on the other hand, IL-6 is also directly capable of inducing osteoclast formation
by a RANKL-independent mechanism [50].
BCP containing strontium presented similar patterns of action on IL-8 than non-strontiated BCP.
The addition of IL-8 to cultures of stromal osteoblastic cells is known to stimulate both RANKL
mRNA expression and protein production, with no effect on the expression of osteoprotegerin, and to
stimulate directly the differentiation of human peripheral blood mononuclear cells into bone-resorbing
osteoclasts [40]. Moreover, IL-8 is also considered to be one of the most potent chemoattractant
molecules that, among several other functions, guides neutrophils through the tissue matrix until
they reach sites of injury [51]. Thanks to these properties, the use of BCP containing strontium
could be clinically interesting if employed as biomaterials to ensure the aseptic state of the site of
operation. This is strengthened by the decreased production of other CXC (i.e., Gro-α) chemokines.
Nevertheless, more studies have to be carried out to determine which CXC cytokine modulation
could explain the results obtained with the screening technique. In fact, apart from CXCL1, little is
known about the activity of CXCL2 and CXCL3 on bone physiology. EGF and RANTES have also
both been implicated in bone remodelling physiology [52]. EGF is able to stimulate the proliferation of
preosteoblastic cells as well as to inhibit their further differentiation into osteoblastic cells. This leads
to osteoblasts which have a wider capability to migrate into the tissues. Moreover, EGF also has the
capability to strongly stimulate osteoclast formation by regulating the expression of OPG and MCP-1 in
osteoblastic cells [53]. On the other hand, RANTES is known to be a potent osteoblast chemoattractant
and a survival-promoting molecule for these cells [54]. It is also known to potently stimulate the
chemotactic recruitment and RANKL-induced differentiation of pre-osteoclasts and to increase the
migration of mature osteoclasts [55]. This dual role tends to lead to an increase in bone remodelling.
The results presented here tend to confirm that human primary bone cells are involved in the host
immune response to particles. BCP particles have been demonstrated to be able to increase the cytokine
production by human primary bone cells and Sr-substitution of BCP may be a promising approach to
reduce such an over-production. This could impact bone remodelling as BCP5% can modulate both
Gro-α and MCP-1 secretion. In vivo studies are needed to confirm those parameters and to test such
biomaterials in a more complex system.
4. Materials and Methods
4.1. Reagents
Dulbecco’s phosphate-buffered saline 1X (DPBS), Trypsin, Ethylenediaminetetraacetic acid
(EDTA), Penicillin, Streptomycin, Dulbecco’s Modified-Eagle Medium (DMEM) + Glutamax,
collagenase II, and foetal calf serum (FCS) were purchased from Invitrogen/Gibco (Life Technologies,
Carlsbad, CA, USA). SrCl2, Ca(NO3)2·4H2O, Sr(NO3)2·4H2O, and P2O5 for the Biphasic Calcium
Phosphate (BCP) and 5% strontium-substituted BCP (BCP5%) powder syntheses were from Sigma
Aldrich Chemicals (St. Louis, MO, USA) and Avocado Research Chemicals (London, UK), respectively.
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The RNeasy Micro Kit and RNase-Free DNase Set were from Qiagen. Power SYBR® Green PCR Master
Mix and High capacity reverse transcription kit were from Applied Biosystems (Life Technologies).
4.2. Cells
Eight femoral heads of bone explants were obtained from the Orthopaedic and Traumatology
department of the University Hospital of Reims, France. Samples were collected after written informed
consent from the donors. The retrieved explants were cut into small pieces, extensively washed in
phosphate-buffered saline, digested in a solution of 0.5X trypsin/EDTA, and then in collagenase II
(140 mg·mL−1). Fragments were then incubated in culture flasks containing Dulbecco’s modified
Eagle medium supplemented with 20% fetal calf serum, 1% antibiotic solution containing penicillin
(10,000 U·mL−1), and streptomycin sulphate (10,000 µg·mL−1) at 37 ◦C in a 5% CO2 humidified
atmosphere. In all experiments, third passage cultures were used. Bone cells were seeded at
a density of 1 × 105 cells per well in 6 well culture plates (BD Falcon). They were cultured in DMEM
supplemented with 10% FCS, 0.5% antibiotic solution penicillin (10,000 IU·mL−1), and streptomycin
sulphate (10,000 µg·mL−1) and incubated at 37 ◦C in a 5% CO2 humidified atmosphere. BCP, BCP5%,
and SrCl2 were added to the culture medium when the cells were confluent. In the present work,
the Surface Area Ratio method (SAR—defined as surface area of material/surface area of cells) was
used to choose the amount of BCP and BCP5% incorporated in human primary bone cell cultures
Based on our previous data, we chose a SAR equal to 1 for both materials in our experiments [9] and
we added a control condition containing 20 µM of SrCl2 at the initial time to have an insight on the
strontium effect independently of the presence of particles [33]. Supernatants were then collected after
7, 14, and 21 days of culture for ELISA and antibody arrays and cells were harvested for PCR arrays
and RT-qPCR studies.
4.3. Biomaterials
The production and characterization of pure and strontium-substituted BCP powders have
been reported previously [9,33]. The particle size range was from 1 to 100 µm (the mean particle
size as determined by laser granulometry was around 30 µm, with significant polydispersity) [9,33].
Briefly, the sol–gel route previously proposed by the authors was used. To produce 2 g of pure HAp
powder, 4.7 g of Ca(NO3)2·4H2O (Aldrich) and 0.84 g of P2O5 (Avocado Research chemicals) were
dissolved in ethanol under stirring and refluxed at 85 ◦C for 24 h. Then, this solution was kept at
55 ◦C for 24 h, to obtain a white consistent gel and was further heated at 80 ◦C for 10 h to obtain
a white powder. Finally, the powder was heated at 1100 ◦C for 15 h. To prepare Sr-substituted
hydroxyapatite, the required amount of Sr(NO3)2 (Aldrich) was added to the solution. In the presented
work, particles were tested and found to be endotoxin-free using the E-toxate kit from Sigma-Aldrich
(Saint-Quentin-Fallavier, Isère, France).
4.4. RNA Purification and Reverse-Transcription
Total RNAs were extracted and cleaned up with RNeasy Micro Kit. Residual genomic DNA was
removed by an on-column DNAse digestion step using a RNase-Free DNase Set. mRNA quantitation
was realized on a Qubit quantitation platform (Invitrogen, Carlsbad, CA, USA) and RNA quality was
checked by gel electrophoresis. Reverse transcription directly followed the use of the high capacity
reverse transcription kit (Applied Biosystems, Carlsbad, CA, USA) on 1 µg of total RNAs.
4.5. Real Time PCR Primer Design and Efficiency Determination
Real time PCR experiments were realized with an ABI7000 thermal cycler (Applied Biosystems).
A calibrator was made by pooling a small amount (5 µL) of all cDNA obtained. Primers were designed
for CCL2 (MCP-1) and CXCL1 (Gro-α) (Table 3). HPRT1 was used as an internal control. For each
Primer couple the specificity and efficiency were determined by testing them against this calibrator.
Results were calculated using the ∆Ct method (data were expressed as the difference of Ct between
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the gene studied and a housekeeping gene (HPRT1)). Data presenting more than one peak in their
melting curves or Cycle threshold over 35 were not considered.
Table 3. Nucleotide sequences of primers used for RT-PCR and reaction efficiency for each
Primer couple.
Targeted
mRNA Sense Primer (5
′-3′) Antisense Primer (5′-3′) Efficiency
CXCL1 TCCTGCATCCCCCATAGTTA CTTCAGGAACAGCCACCAGT 1.97
CCL2 AGTCTCTGCCGCCCTTCT GTGACTGGGGCATTGATTG 1.98
HPRT1 TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT 1.99
4.6. Enzyme-Linked Immunosorbent Assay (ELISA)
MCP-1 and Gro-α concentrations were measured in culture supernatants coming from
8 independent donors using the DuoSet ELISA kit (R & D Systems), following the manufacturer’s
instructions. Controls included supernatant from non-stimulated cells and medium alone.
4.7. Antibody Cytokine Arrays
Cytokine antibody arrays (“Human Cytokine Array C3”, Raybiotech, Norcross, GA, USA)
were performed after 7, 14, and 21 days of culture according to the manufacturer’s instructions.
Briefly, 10-fold diluted culture supernatants coming from 3 independent donors or medium alone
were incubated on antibody-coated membranes before detection with a streptavidin-horseradish
peroxidase biotinylated-antibody complex and chemiluminescence detection on X-ray films for 2 min.
The integrated optical density (IOD) of each dot was measured on digitalized autoradiograms with
the ImageJ software (1.50i, National Institutes of Health, Bethesda, MD, USA) after subtraction of
the non-specific signal. Each value corresponds to the ratio between the dot studied and the internal
positive control (expressed as the average of six internal control dots). Values under the detection
threshold (determined by the maximum value of the negative internal control dots) were considered
as non-achievable (NA). Data were calculated as the average level of secretion (arbitrary units) for
each mediator normalized with internal positive controls and internal negative control.
4.8. Statistics
The significance of the results was assessed with exact nonparametric and stratified Wilcoxon
Mann Whitney tests (StatXact 7.0, Cytel Inc., Cambridge, MD, USA). We used nonparametric statistics
owing to a lack of normal distribution of the assessed variables. Stratification allowed the impact of
donor variability to be taken into account. Differences were considered significant at p < 0.05.
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